Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company has shown significant year-on-year growth in performance, with a notable increase in overseas building materials sales [5][6] - The company's revenue for the first half of 2025 reached 8.19 billion yuan, representing a 49.0% increase year-on-year, while net profit attributable to shareholders increased by 63.9% to 750 million yuan [4][5] - The overseas building materials segment has been a key driver of growth, with revenue from this segment reaching 5.45 billion yuan, accounting for 66.5% of total revenue [5][6] Summary by Sections Revenue Performance - The company reported a substantial increase in revenue and net profit for the first half of 2025, with Q2 figures showing a 50.8% increase in revenue and a 178.5% increase in net profit [4][5] - The gross profit margin for the first half of 2025 was 29.3%, up 3.7 percentage points year-on-year, while the net profit margin was 13.9%, an increase of 3.8 percentage points [5] Overseas Building Materials - The production of ceramic products reached approximately 98 million square meters, a year-on-year increase of about 17.0%, with overseas building materials revenue growing by 90.1% [6] - The company has been expanding its production capacity in several African countries, with ongoing technical upgrades and new projects expected to enhance profitability further [6] Construction Machinery - The construction machinery segment generated revenue of 2.57 billion yuan, a decrease of 5.0% year-on-year, but maintained resilience in traditional markets while expanding into new regions [7] - The gross profit margin for this segment improved to 26.2%, up 1.3 percentage points year-on-year [7] Lithium Industry - The company's stake in Blue Lithium Industry saw a significant increase in net profit margin from 18.8% to 31.0%, despite a decline in revenue due to price impacts [8] - The expected rise in lithium prices may provide upward momentum for the company's performance [8] Financial Forecasts - The company forecasts net profits of 1.52 billion yuan, 1.68 billion yuan, and 1.84 billion yuan for 2025, 2026, and 2027 respectively [9] - Revenue is projected to grow from 12.6 billion yuan in 2024 to 19.8 billion yuan in 2027, with a compound annual growth rate of approximately 14.94% [9]

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company has shown significant improvement in profits in Q2 2025, with a notable recovery in net profit compared to Q1 2025 [1][10]. - The chairman's active involvement in management is expected to drive positive changes in the company's performance in the second half of the year [10]. - The company is undergoing a transformation towards an "efficiency-oriented" approach, which has led to a significant reduction in sales expense ratios [9][10]. Financial Performance Summary - For the first half of 2025, the company reported revenues and net profits of 2.26 billion and 220 million yuan, respectively, reflecting year-on-year declines of 19.6% and 35.4% [4]. - Q2 2025 saw revenues and net profits of 1.18 billion and 120 million yuan, with a year-on-year decline of 18.4% in revenue but a 20.9% increase in net profit [4]. - The company's gross margin for the first half of 2025 was 71.0%, down 3.5 percentage points year-on-year [8]. Business Segment Performance - The raw materials segment showed resilience, with revenue of 630 million yuan, a slight decline of 0.6% year-on-year, while the medical terminal products segment generated 670 million yuan, down 9.4% [5]. - The skin science innovation transformation business experienced a significant decline of 34.0% in revenue, totaling 910 million yuan, while the nutrition science innovation transformation business grew by 32.4% to 40 million yuan [5]. - The company launched several new medical aesthetic products in 2025, contributing to a diversified product matrix [6]. Market Outlook - The company is expected to return to a positive growth trajectory, with revenue forecasts adjusted to 4.825 billion, 5.631 billion, and 6.735 billion yuan for 2025, 2026, and 2027, respectively [11]. - The report anticipates that the company's earnings per share (EPS) will be 0.98, 1.23, and 1.66 yuan for 2025, 2026, and 2027, respectively [11]. - The chairman's plan to increase shareholding by 200 to 300 million yuan within six months reflects confidence in the company's future development [11].

A 股：买入（维持） 当前价：41.66 元人民币 H 股：买入（维持） 2025 年 8 月 28 日 公司研究 新业务价值增幅走阔，OCI 股票占比显著提升 ——中国人寿（601628.SH、2628.HK）2025 年半年报点评 当前价：23.88 港币 作者 分析师：王一峰 执业证书编号：S0930519050002 010-57378038 wangyf@ebscn.com 分析师：黄怡婷 执业证书编号：S0930524070003 010-57378023 huangyiting@ebscn.com | 市场数据（A 股） | | | --- | --- | | 总股本(亿股) | 282.65 | | 总市值(亿元)： | 11775.08 | | 一年最低/最高(元)： | 32.37/50.88 | | 近 3 月换手率： | 7.2% | 股价相对走势 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | -8.5 | -4.9 | -3.7 | | 绝对 | -2.4 | 9.4 | 29.0 | 资料来 ...

2025 年 8 月 28 日 公司研究 投资与承保共同推动盈利增长 32% ——中国财险（2328.HK）2025 年半年报点评 买入（维持） 当前价：18.22 港元 作者 分析师：王一峰 执业证书编号：S0930519050002 010-57378038 wangyf@ebscn.com 分析师：黄怡婷 执业证书编号：S0930524070003 010-57378023 huangyiting@ebscn.com 市场数据 盈利增速承压，COR 优于同业——中国财险 （ 2328.HK ） 2024 年 一 季 报 点 评 （2024-04-30） 要点 事件： 2025 年上半年，中国财险原保险保费收入 3232.8 亿元，同比+3.6%；保险服务收 入 2490.4 亿元，同比+5.6%；归母净利润 244.5 亿元，同比+32.3%；承保综合成 本率 94.8%，同比-1.4pct；总投资收益率（非年化）2.6%，同比+0.4pct；拟派发 中期股息每股 0.24 元，同比+15.4%。 | 总股本(亿股) | 222.43 | | --- | --- | | 总市值(亿元港币)： | 405 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company achieved a robust performance in the first half of 2025, with revenue and net profit increasing by 31.3% and 36.1% year-on-year, respectively [4] - The introduction of new fragrance products has further strengthened the company's high-end beauty positioning [8] - The company has successfully improved its operational efficiency, leading to a significant decrease in expense ratios [6][9] - The online and offline channels have both shown strong growth, with online sales increasing by 39% and offline sales by 26.6% [5] Financial Performance - In the first half of 2025, the company reported revenue of 2.59 billion yuan and a net profit of 670 million yuan, with an earnings per share (EPS) of 1.37 yuan [4] - The gross profit margin slightly decreased to 84.2%, while the net profit margin improved to 25.9% [6] - The company’s operating cash flow reached 830 million yuan, reflecting a year-on-year increase of 34.2% [7] Product and Channel Analysis - The revenue breakdown for the first half of 2025 shows that color cosmetics, skincare, fragrance, and makeup artistry training contributed 55%, 42%, 0.4%, and 2.6% to total revenue, respectively [5] - The company has expanded its offline presence with 405 self-operated counters and 32 distributor counters, marking a net increase of 27 and 1, respectively [5] Future Outlook - The company expects continued high-quality growth, with revised net profit forecasts for 2025, 2026, and 2027 set at 1.21 billion, 1.58 billion, and 2.04 billion yuan, respectively [9] - The current stock price corresponds to a price-to-earnings (P/E) ratio of 36 for 2025, indicating a favorable valuation [9]

Investment Rating - The report maintains a "Buy" rating for both A-shares and H-shares of the company, with current prices at 8.63 CNY and 7.39 HKD respectively [1]. Core Views - The company demonstrates resilience in its performance despite fluctuations in oil prices, attributed to its integrated industry chain advantages [7][17]. - The company plans to enhance its natural gas business and overall operational efficiency through strategic acquisitions and capital investments [16][18]. Summary by Sections Financial Performance - In the first half of 2025, the company reported total revenue of 1,450.1 billion CNY, a year-on-year decrease of 6.7%, and a net profit attributable to shareholders of 84 billion CNY, down 5.4% [5]. - The company achieved an operating cash flow of 227.1 billion CNY, reflecting a year-on-year increase of 4.0% [7]. Business Segments - The upstream segment generated an operating profit of 85.7 billion CNY, down 6.5% year-on-year, primarily due to falling oil prices [8]. - The natural gas sales segment saw an operating profit of 18.6 billion CNY, up 10.8% year-on-year, benefiting from increased sales volume [10]. - The refining and chemical segment reported an operating profit of 11.1 billion CNY, down 18.9% year-on-year, impacted by reduced margins and inventory losses [11]. Strategic Initiatives - The company is set to acquire three gas storage companies to enhance its natural gas supply chain, which is expected to add 10.97 billion cubic meters of working gas capacity [16]. - The company plans to maintain high capital expenditures, with a budget of 210 billion CNY for upstream investments in 2025, aiming for a 1.6% increase in oil and gas equivalent production [17]. Dividend Policy - The company plans to distribute a cash dividend of 0.22 CNY per share, maintaining a dividend payout ratio of 47.9%, reflecting its commitment to shareholder returns [14]. Profit Forecast and Valuation - The report forecasts net profits of 166.1 billion CNY, 171.2 billion CNY, and 175.7 billion CNY for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.91 CNY, 0.94 CNY, and 0.96 CNY [18][20].

2025 年 8 月 28 日 晨会速递 分析师点评 重点交流 【海外 TMT】精密线缆解决方案商，立讯控股赋能"数据中心+汽车"业务发展—— 汇聚科技（1729.HK）首次覆盖报告(买入) 汇聚科技是定制电线互连方案供应商，立讯精密是控股股东。基于：1）AI 算力维持 景气度，公司数据中心电线组件、特种线缆、服务器 ODM 业务收入持续高速增长； 2）汽车智能化趋势推动汽车线缆需求高速增长，Leoni K 与公司汽车线束相关业务 有望持续发挥渠道、技术等协同效应。我们认为公司具备一定的标的稀缺性和溢价空 间，首次覆盖，给予汇聚科技"买入"评级。 总量研究 【宏观】"反内卷"推动制造业盈利好转——2025 年 7 月工业企业盈利数据点评 7 月受利润率改善推动，工业企业利润同比降幅继续收窄。结构上，原材料行业利润 同比增速大幅反弹，主要受益于"反内卷"政策推动原材料价格上涨。当前随着"反 内卷"政策逐步落地，对于投资端调控、治理低价无序竞争的效果陆续显现，制造业 利润率迎来好转，未来随着市场供需关系的逐步调节，企业将陆续摆脱"以价换量" 局面，企业盈利也将迎来曙光。 行业研究 【建筑】周观点：上海发布楼市新政 ...

Investment Rating - The report maintains a "Buy" rating for Qingdao Beer (600600.SH) with a current price of 69.78 CNY [1] Core Views - Qingdao Beer achieved a revenue of 20.49 billion CNY in H1 2025, a year-on-year increase of 2.1%, and a net profit attributable to shareholders of 3.9 billion CNY, up 7.2% year-on-year [5][9] - The company continues to experience steady sales growth and cost advantages, with a focus on product structure optimization and market expansion [6][8] Sales Performance - In H1 2025, sales volume reached 4.73 million kiloliters, a year-on-year increase of 2.3%, driven by inventory reduction and a focus on market share [6] - The average selling price in H1 2025 was 4,330 CNY per kiloliter, showing a slight decrease of 0.1% year-on-year [6] Product Structure and Market Strategy - The high-end product trend continues, with mid-to-high-end products showing significant growth, achieving a sales volume of 1.99 million kiloliters, up 5.1% year-on-year [6] - The company is actively expanding into emerging channels and enhancing online operations, with five consecutive years of rapid growth in transaction volume [6] Cost and Profitability - The gross margin for H1 2025 was 43.7%, an increase of 2.09 percentage points year-on-year, primarily due to lower raw material prices [7] - The net profit margin reached 19.39% in H1 2025, reflecting an increase of 0.85 percentage points year-on-year [7] Strategic Initiatives - The new management team emphasizes sales growth as a primary goal, implementing a product mix strategy to enhance core products and expand into new markets [8] - The company is focusing on the southern market and international expansion in regions like South Korea and West Africa to drive overall sales growth [8] Financial Forecast and Valuation - The report projects net profits for 2025-2027 at 4.72 billion CNY, 5.04 billion CNY, and 5.29 billion CNY respectively, with corresponding EPS of 3.46 CNY, 3.70 CNY, and 3.88 CNY [9][10] - The current stock price corresponds to a P/E ratio of 20x for 2025, indicating a strong position in the beer industry with robust channel and brand advantages [9]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong potential for investment returns exceeding the market benchmark by more than 15% over the next 6-12 months [4][6]. Core Insights - The company reported a significant revenue increase of 34.4% year-on-year for the first half of 2025, reaching 550 million yuan, with a net profit of 42 million yuan, reflecting a 19.6% growth [1][2]. - The pressure sensor business is identified as a major growth driver, with a revenue increase of 61.9% year-on-year, contributing 52.8% to total revenue [3]. - The company is actively investing in research and development for force sensors, establishing a dedicated team and production line to enhance its product offerings in this area [3][4]. Summary by Sections Financial Performance - In Q2 2025, the company achieved a revenue of 290 million yuan, a 28.2% increase year-on-year, with a net profit of 22 million yuan, showing a 3.1% decline compared to the previous year [1][2]. - The gross margin for the pressure sensor segment decreased by 2.2 percentage points to 27.4%, while the overall gross margin fell by 2.9 percentage points to 27.8% [2][3]. Product Development - The company is expanding its product line in force sensors, including six-dimensional force sensors and torque sensors, targeting applications in automotive and robotics sectors [3][4]. - R&D expenses increased by 45.2% year-on-year, now accounting for 6.9% of total revenue, reflecting a commitment to innovation [2]. Profit Forecast and Valuation - The net profit forecast for 2025 has been adjusted downwards to 110 million yuan, a decrease of 8.8%, while forecasts for 2026 and 2027 have been raised to 140 million yuan and 190 million yuan, respectively [4]. - The current stock price corresponds to a PE ratio of 112 for 2025, 83 for 2026, and 64 for 2027, indicating potential for future earnings growth [4].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company achieved significant revenue and profit growth in the first half of 2025, with revenue reaching 1.459 billion yuan, a year-on-year increase of 28.2%, and net profit of 156 million yuan, up 34.9% [5] - Operating cash flow for the first half of 2025 was 410 million yuan, reflecting an 84.4% year-on-year increase [5] - The company continues to expand its business model through both organic growth and acquisitions, with the integration of the acquired brand NaiRuiEr showing positive results [10] Revenue Performance - The company’s three main business segments showed strong performance: Beauty and Health Services, Medical Aesthetic Services, and Sub-health Medical Services, with respective revenues of 810 million, 500 million, and 150 million yuan, representing year-on-year growth of 29.6%, 13.0%, and 107.8% [6] - Direct sales and franchise models contributed to revenue growth, with direct sales revenue reaching 740 million yuan, up 31.0% year-on-year, and franchise revenue at 70 million yuan, up 16.2% [6] Customer Engagement - Direct sales stores saw a customer footfall of 850,000, a 48.6% increase year-on-year, and active membership grew to 112,000, up 45.7% [6] - The medical aesthetic segment also showed resilience, with foot traffic of 50,000 and active members of 24,000, reflecting year-on-year growth of 28.0% and 27.6% respectively [6] Business Expansion - The company expanded its sub-health medical services, with foot traffic reaching 19,000, a 75.5% increase, and active members growing by 93.4% [7] - The revenue from the functional medicine segment increased by 122.0% year-on-year, driven by new product lines [7] Profitability - The overall gross margin improved by 2.3 percentage points to 49.3%, and the net profit margin increased by 0.5 percentage points to 10.7% [8] - The gross margins for the three business segments were 42.1%, 56.9%, and 63.1%, with respective year-on-year increases of 1.8, 1.8, and 8.7 percentage points [9] Future Outlook - The company plans to continue its dual strategy of organic growth and acquisitions, with a focus on expanding its beauty and health brand matrix and enhancing its medical services [10] - The forecast for net profit for 2025-2027 has been adjusted upwards to 310 million, 350 million, and 410 million yuan, with corresponding EPS estimates of 1.30, 1.48, and 1.72 yuan [10]